アブカムでは最適な動作のために Google Chrome など最新ブラウザでの閲覧を推奨します。
Prostate cancer is the most frequently diagnosed cancer and is the second leading cause of cancer-related deaths in American men. Although the early serum detection of prostate-specific antigen (PSA) plays important roles in early diagnosis, it may not distinguish prostate cancer from benign diseases. Recently, a novel protein, which contains 339 amino acids, named STEAP (six transmembrane epithelial antigen of the prostate), was identified in advanced prostate cancer. STEAP is unique among the currently known prostate cancer markers because of its putative secondary structure, from which one may predict that it functions as a potential channel protein. STEAP is strongly expressed in advanced prostate cancer and some extent expression in other cancers, such as colon and ovarian cancer cell lines.
Our Abpromise guarantee covers the use of ab3679 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 0.5 - 2 µg/ml. Detects a band of approximately 40 kDa (predicted molecular weight: 38 kDa).|
|IP||Use at an assay dependent dilution.|
|ELISA||Use at an assay dependent dilution.|
ab3679 has not yet been referenced specifically in any publications.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"